Found: 13
Select item for more details and to access through your institution.
P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 889, doi. 10.1002/cpdd.1088
- By:
- Publication type:
- Article
P2‐372: IMAGING ALZHEIMER'S TAU PATHOLOGY IN HUMANS: [18F]JNJ‐067—A PHASE 0 EXPLORATORY STUDY IN HEALTHY VOLUNTEERS AND SUBJECTS WITH PROBABLE ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P838, doi. 10.1016/j.jalz.2018.06.1063
- By:
- Publication type:
- Article
IC‐P‐220: CLINICAL UPDATE: <sup>18</sup>F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P179, doi. 10.1016/j.jalz.2018.06.2287
- By:
- Publication type:
- Article
Lumbar ADR: A triumph of technology over reason?
- Published in:
- JAAPA: Journal of the American Academy of Physician Assistants (Haymarket Media, Inc.), 2007, v. 20, n. 8, p. 30, doi. 10.1097/01720610-200708000-00011
- By:
- Publication type:
- Article
FIRST-IN-HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18-F PI-2620 IN ALZHEIMER’S DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P3, doi. 10.1016/j.jalz.2017.06.2625
- By:
- Publication type:
- Article
Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
- Published in:
- Cephalalgia, 2024, v. 44, n. 8, p. 1, doi. 10.1177/03331024241259456
- By:
- Publication type:
- Article
Evaluation of dosimetry, quantitative methods and test-retest variability of <sup>18</sup>F-PI-2620 PET for the assessment of tau deposits in the human brain.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.236240
- By:
- Publication type:
- Article
Tau PET imaging with <sup>18</sup>F-PI-2620 in patients with Alzheimer’s disease and healthy controls: a first-in-human study.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.236224
- By:
- Publication type:
- Article
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 6, p. 1044, doi. 10.1002/psp4.13140
- By:
- Publication type:
- Article
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 9, p. 1153, doi. 10.1111/head.14389
- By:
- Publication type:
- Article
Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 10, p. 1, doi. 10.1111/cts.70015
- By:
- Publication type:
- Article
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 7, p. 1, doi. 10.1111/cts.13813
- By:
- Publication type:
- Article
Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 13, p. 3176, doi. 10.1007/s00259-020-04880-1
- By:
- Publication type:
- Article